1. Tumours of the lacrimal gland. Epidemiological, clinical and genetic characteristics.
- Author
-
von Holstein SL
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Biopsy, Child, Child, Preschool, Denmark epidemiology, Female, Gene Expression Regulation, Neoplastic, Humans, Incidence, Lacrimal Apparatus anatomy & histology, Lacrimal Apparatus pathology, Lacrimal Apparatus physiology, Male, Middle Aged, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Young Adult, Adenoma, Pleomorphic epidemiology, Adenoma, Pleomorphic genetics, Adenoma, Pleomorphic pathology, Carcinoma, Adenoid Cystic epidemiology, Carcinoma, Adenoid Cystic genetics, Carcinoma, Adenoid Cystic pathology, Carcinoma, Mucoepidermoid epidemiology, Carcinoma, Mucoepidermoid genetics, Carcinoma, Mucoepidermoid pathology, Lacrimal Apparatus Diseases epidemiology, Lacrimal Apparatus Diseases genetics, Lacrimal Apparatus Diseases pathology, Orbital Neoplasms epidemiology, Orbital Neoplasms genetics, Orbital Neoplasms pathology
- Abstract
Tumours of the lacrimal gland are rare, but the prognosis may be grave. To date, no population-based incidence and distribution data on lacrimal gland tumours exist. In addition, almost nothing is known about the genetic profile of epithelial tumours of the lacrimal gland. We collected specimens and clinical files on all biopsied lacrimal gland lesions in Denmark over a 34-year period and re-evaluated the diagnosis to provide updated population-based incidence rates and epidemiological characteristics. Clinical data regarding symptoms, clinical examinations, treatment and follow-up were collected for patients with adenoid cystic carcinoma (ACC), pleomorphic adenoma (PA), carcinoma ex pleomorphic adenoma (Ca-ex-PA) and mucoepidermoid carcinoma (MEC). Using RT-PCR, FISH, immunohistochemistry, Q-PCR and high-resolution array-based comparative genomic hybridization (arrayCGH) we explored the genetic characteristics including copy number alterations (CNA) in ACC, PA, Ca-ex-PA and MEC. The incidence of biopsied lacrimal gland lesions was 1.3/1,000,000/year, and ~50% were neoplastic lesions. Of these, 55% were malignant tumours with epithelial tumours as the most frequent. The overall incidence was increasing, and this was caused by an increase in biopsied non-neoplastic lesions. We found that 10/14 ACCs either expressed the MYB-NFIB fusion gene and/or had rearrangements of MYB. All ACCs expressed the MYB protein. ACC was characterized by recurrent copy number losses involving 6q, 12q and 17q and gains involving 19q, 8q and 11q. ArrayCGH revealed an apparently normal genomic profile in 11/19 PAs. The remaining 8 PAs had recurrent copy number losses involving 1p, 6q, 8q and 13q and gain involving 9p. PA expressed PLAG1 in all tumours whereas only 2/29 tumours expressed HMGA2. Ca-ex-PA was characterized by recurrent copy number gain involving 22q. PLAG1 was expressed in 3/5 Ca-ex-PA whereas none of these tumours expressed HMGA2. MEC expressed the CRTC1-MAML2, and this fusion was found to be tumour-specific for lacrimal gland MEC. In conclusion, lacrimal gland lesions that require pathological evaluation are rare in the Danish population, and the incidence rate of biopsied benign lesions is increasing. Epithelial tumours of the lacrimal gland are molecularly very similar to their salivary gland counterparts in the expression of the tumour-specific fusion genes and in their genomic imbalances as demonstrated by arrayCGH. MYB-NFIB is a useful biomarker for ACC and MYB, and its downstream target genes may be potential therapeutic targets for these tumours., (© 2013 The Author Acta Ophthalmologica © 2013 Acta Ophthalmologica Scandinavica Foundation.)
- Published
- 2013
- Full Text
- View/download PDF